Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its CEO, Dr Werner Lanthaler, will present at the BioCapital Europe 2016 in Amsterdam, The Netherlands, and at the 28th Annual Roth Conference in Dana Point, CA, USA.
BioCapital Europe 2016, Sofitel Legend Amsterdam The Grand in Amsterdam
Date: Wednesday, 09 March 2016,
03.00 pm CET
Venue: Sofitel Legend Amsterdam The Grand, Amsterdam,
The Netherlands
Presenter: Dr Werner Lanthaler,
Chief Executive Officer of Evotec AG
28th Annual Roth Conference, The Ritz Carlton in Dana Point, CA
Date: Tuesday, 15 March 2016,
01.00 pm PDT (9:00 pm CET)
Venue: The Ritz Carlton, Dana Point, CA, USA
Presenter: Dr Werner Lanthaler,
Chief Executive Officer of Evotec AG
The PDF version and the direct link to the webcast of the presentation at 28th Annual Roth Conference will be provided at http://www.evotec.com/.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology, inflammation and infectious diseases. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca, Roche and UCB. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim and MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and with Roche in the field of Alzheimer's disease. For additional information please go to www.evotec.com.
FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.
| Language: | English | ||
| Company: | Evotec AG | ||
| Manfred Eigen Campus / Essener Bogen 7 | |||
| 22419 Hamburg | |||
| Germany | |||
| Phone: | +49 (0)40 560 81-0 | ||
| Fax: | +49 (0)40 560 81-222 | ||
| E-mail: | |||
| Internet: | |||
| ISIN: | DE0005664809 | ||
| WKN: | 566480 | ||
| Indices: | TecDAX | ||
| Listed: | Regulated Market in Frankfurt (Prime Standard); | ||
| Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, | |||
| Munich, Stuttgart; Terminbörse EUREX |
View source version on businesswire.com: http://www.businesswire.com/news/home/20160303005615/en/
Contacts:
Gabriele Hansen
VP Corporate Communications &
Investor Relations
Phone: +49.(0)40.56081-255
gabriele.hansen@evotec.com
